Develop New TCR-Based therapies and biomarkers

TCR Discovery Platform

T-cell receptor (TCR)-based therapies have the potential to target intracellular antigens presented by HLA, broadening the scope of application of conventional cell therapies, in immuno-oncology and auto-immune diseases.

However, there are challenges to address: (i) Detect low frequency antigen-specific TCR, (ii) Ensure antigen specificity, (iii) Avoid cross-specificity to protect healthy tissue

Our innovative platform, addresses this limitation by amplifying and identifying these low frequency antigen-specific T cells, boosted by in silico data science and AI-based tools.

Objectives: Explore new indications, Develop new modalities, Reposition existing therapy, Assess immunogenicity

Two Steps:

DISCOVERY: Hit generation
OPTIMIZATION: Hit to Leads

DISCOVERY: Hit Generation

Our fully integrated wet lab workflow leverages cutting edge technologies, to isolate and generate T cell populations from biological samples, with exhaustive information on their phenotypes.

Using robust data science pipelines, we generate an exhaustive list of TCRs, along with gene expression, cell surface protein expression, and antigen specificity.

Key technological pillars: Cell Culture, Cytometry, Cell sorting & SingleCell Multiomics sequencing

OPTIMIZATION: Hit to Leads

From the list of TCRs, our insilico omics platform is taking over the optimization phase. Our tested pipelines, are boosted by proprietary data and external cured datasets. This will streamline and support the selection of TCR candidates for further development.

Duly informed with various scoring and readouts, such as specificity, structural properties, or cross-reactivity, these selected candidates are ready for in vivo & in vitro testing, by Parean or Partners.

Key technological pillars: External & Proprietary TCR Databases, AI-powered Tools

Reach Out to Learn More !